Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹85,781 Cr
P/E Ratio
18.91
P/B Ratio
3.76
Industry P/E
36.67
Debt to Equity
0.04
ROE
20.52 %
ROCE
24.9 %
Div. Yield
0.35 %
Book Value
226.88
EPS
45.06
CFO
₹20,646.60 Cr
EBITDA
₹30,024.50 Cr
Net Profit
₹19,752.20 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Zydus Lifesciences
| -12.25 | -7.17 | -13.51 | -7.53 | 33.11 | 19.89 | 9.26 |
|
BSE Sensex
| 1.72 | 3.50 | 4.95 | 8.90 | 11.18 | 21.04 | 11.14 |
|
BSE Healthcare
| -6.38 | 0.39 | -0.68 | 22.84 | 19.04 | 22.87 | 9.79 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Zydus Lifesciences
| 38.98 | 64.11 | -13.08 | 0.99 | 87.51 | -27.35 | -19.44 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1,528.20 | 1,23,415.53 | 24.73 | 18.12 | |
| 2,579.50 | 1,06,261.66 | 52.05 | 20.49 | |
| 1,747.40 | 4,19,223.80 | 36.67 | 17.76 | |
| 3,246.40 | 1,09,834.01 | 58.99 | 25.93 |
Who made the right move - FPI or MF?
4 min read•By Yash Rohra
5 min read•By Jugal Harpalani
1 min read•By Research Desk
2 min read•By Mohammed Ekramul Haque
2 min read•By Mohammed Ekramul Haque
2 min read•By Mohammed Ekramul Haque
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products... segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company offers the products under the Everyuth and Nutralite, Complan, Glucon D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust. Read more
Incorporated
1995
Chairman
Pankaj R Patel
Managing Director
Sharvil P Patel
Group
Cadila
Headquarters
Ahmedabad, Gujarat
Website
Looking for more details about Zydus Lifesciences Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsRumour verification - Regulation 30(11)
16-Apr-2025Clarification sought from Zydus Lifesciences Ltd
16-Apr-2025
The total asset value of Zydus Lifesciences Ltd stood at ₹ 31,446 Cr as on 31-Dec-24
The share price of Zydus Lifesciences Ltd is ₹852.70 (NSE) and ₹852.50 (BSE) as of 22-Apr-2025 IST. Zydus Lifesciences Ltd has given a return of 33.11% in the last 3 years.
Zydus Lifesciences Ltd has a market capitalisation of ₹ 85,781 Cr as on 22-Apr-2025. As per Value Research classification, it is a Large Cap company.
The P/B ratio of Zydus Lifesciences Ltd is 3.76 times as on 22-Apr-2025, a 28% discount to its peers’ median range of 5.25 times.
The P/E ratio of Zydus Lifesciences Ltd is 18.91 times as on 22-Apr-2025, a 48% discount to its peers’ median range of 36.67 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Zydus Lifesciences Ltd and enter the required number of quantities and click on buy to purchase the shares of Zydus Lifesciences Ltd.
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company offers the products under the Everyuth and Nutralite, Complan, Glucon D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.
The promoter of Zydus Lifesciences Ltd is Zydus Family Trust (Pankaj R. Patel, Pritiben P. Patel and Sharvil P. Patel-Trustees). Zydus Family Trust (Pankaj R. Patel, Pritiben P. Patel and Sharvil P. Patel-Trustees) owns 74.96 per cent of the total equity. The chairman of the company is Pankaj R Patel , and the managing director is Sharvil P Patel..
There is no promoter pledging in Zydus Lifesciences Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
4,20,136
|
|
|
1,22,394
|
|
|
1,10,159
|
|
|
1,06,555
|
| Zydus Lifesciences Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
21.77
|
|
Operating margin(%)
|
25.3
|
|
Net Margin(%)
|
20.28
|
|
Dividend yield(%)
|
0.35
|
Yes, TTM profit after tax of Zydus Lifesciences Ltd was ₹4,537 Cr.
₹7.35
(
